OKT3
Trials 7
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2019-06-24 | Tiziana Life Sciences LTD | Results Newly Published Article Reporting Clinical Activity of Orally Administered OKT3, a Mouse Anti-CD3 Monoclonal Antibody, in Moderate to Severe Ulcerative Colitis Patients, Supports Tiziana’s Oral Monoclonal Antibody Platform tizianalifesciences.com ↗
Third party research conducted by leading U.S. institutions to be published in a peer reviewed journal Crohn’s & Colitis 360 shows orally administered anti-CD3 resulted in anti-inflammatory gene expression with no serious treatment related adverse events up to a dose of 1 mg of OKT3 |
| 1996-09-01 | 7 Hills Pharma, LLC | Results Alpha 4 beta 1 (CD49d/CD29) integrin costimulation of human T cells enhances transcription factor and cytokine induction in the absence of altered sensitivity to anti-CD3 stimulation 7hillspharma.com ↗
Furthermore, the dose of OKT3 required to achieve half-maximal activation was the same using PMA or different concentrations of alpha 4 beta 1 ligands. |
All press releases naming this drug 2 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OKT3 | “Haploidentical stem cell transplant recipients will receive a reduced intensity conditioning regimen consisting of OKT-3, Fludarabine, Thiotepa , and Melphalan followed by an...” NCT00145587 ↗18“Transplant recipients received a reduced intensity conditioning regimen consisting of OKT-3, fludarabine, thiotepa, and melphalan followed by an infusion of a T-cell depleted...” NCT00143559 ↗ “Approximately 10 days prior to the transplant procedure, all participants received the same preparative regimen consisting of Busulfan, cyclophosphamide, low-dose thiotepa, and OKT3.” NCT00152113 ↗ “Transplant recipients received a myeloablative conditioning regimen consisting of total body irradiation, thiotepa, cyclophosphamide, ATG, and OKT3.” NCT00186823 ↗ “Transplant recipients received a non-TBI based reduced intensity conditioning regimen consisting of OKT-3, Fludarabine Thiotepa, and Melphalan.” NCT00145613 ↗ “Anti-CD3 Murine Monoclonal Antibody OKT3, MOAB OKT3; with Cyclophosphamide, CTX, NSC-26271” NCT00002482 ↗ “the other arm utilized negative selection with the anti-CD3 antibody OKT-3” NCT00186823 ↗ “anti-CD3 monoclonal antibody (OKT3)” NCT00004022 ↗ “OKT-3 (5mg/d) from day -5 to day +3” NCT01220544 ↗ “OKT3” NCT00145626 ↗ |
| Known as | MOAB OKT3 | “Anti-CD3 Murine Monoclonal Antibody OKT3, MOAB OKT3; with Cyclophosphamide, CTX, NSC-26271” NCT00002482 ↗ |
| Known as | Muromonab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00566696 ↗ |
| Known as | Muromonab-CD3 | “Study participants will receive a non-TBI based preparative regimen consisting of Cyclophosphamide, fludarabine, thiotepa, melphalan, and muromonab-CD3 (OKT3) followed by an...” NCT00145626 ↗ |
| Action | Deplete | “Muromonab-CD3 has been shown to reduce the number of lymphocytes” NCT00027443 ↗ |
| Modality | Monoclonal antibody | “Anti-CD3 Murine Monoclonal Antibody” NCT00002482 ↗ |
| Route | Intravenous | “muromonab-CD3 IV once daily for 10 days” NCT00004482 ↗ |